Nevertheless, Fransen et al. described efficient systemic activation of tumor-specific T cells by the peri-tumoral administration of CTLA-4-blocking antibodies in the lipid-based adjuvant montanide [213, 236]. This evidence concerns the gene CTLA4 and neoplasm.